HomeComparePVTTF vs EQR

PVTTF vs EQR: Dividend Comparison 2026

PVTTF yields 111111.11% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PVTTF wins by $1.3838190899465547e+27M in total portfolio value
10 years
PVTTF
PVTTF
● Live price
111111.11%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.3838190899465547e+27M
Annual income
$1,381,373,456,343,941,000,000,000,000,000,000.00
Full PVTTF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — PVTTF vs EQR

📍 PVTTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPVTTFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PVTTF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PVTTF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PVTTF
Annual income on $10K today (after 15% tax)
$9,444,444.44/yr
After 10yr DRIP, annual income (after tax)
$1,174,167,437,892,349,800,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, PVTTF beats the other by $1,174,167,437,892,349,800,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PVTTF + EQR for your $10,000?

PVTTF: 50%EQR: 50%
100% EQR50/50100% PVTTF
Portfolio after 10yr
$6.919095449732774e+26M
Annual income
$690,686,728,171,970,500,000,000,000,000,000.00/yr
Blended yield
99.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PVTTF
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PVTTF buys
0
EQR buys
0
No recent congressional trades found for PVTTF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPVTTFEQR
Forward yield111111.11%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1.3838190899465547e+27M$47.8K
Annual income after 10y$1,381,373,456,343,941,000,000,000,000,000,000.00$5,475.61
Total dividends collected$1.383658847866035e+27M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PVTTF vs EQR ($10,000, DRIP)

YearPVTTF PortfolioPVTTF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,121,811$11,111,111.11$11,380$679.82+$11.11MPVTTF
2$11,561,029,218$11,549,128,879.66$13,014$837.25+$11561.02MPVTTF
3$11,232,204,364,934$11,219,834,063,671.13$14,961$1,036.20+$11232204.35MPVTTF
4$10,199,601,320,781,262$10,187,582,862,110,782.00$17,297$1,289.22+$10199601320.76MPVTTF
5$8,656,721,364,988,387,000$8,645,807,791,575,153,000.00$20,121$1,613.15+$8656721364988.37MPVTTF
6$6,867,176,795,058,000,000,000$6,857,914,103,197,462,000,000.00$23,561$2,030.84+$6867176795058000.00MPVTTF
7$5,091,669,942,459,710,000,000,000$5,084,322,063,288,997,000,000,000.00$27,783$2,573.54+$5091669942459709440.00MPVTTF
8$3,528,599,356,203,225,300,000,000,000$3,523,151,269,364,793,600,000,000,000.00$33,013$3,284.39+$3.5285993562032256e+21MPVTTF
9$2,285,638,880,947,370,600,000,000,000,000$2,281,863,279,636,233,000,000,000,000,000.00$39,547$4,223.51+$2.2856388809473705e+24MPVTTF
10$1,383,819,089,946,554,900,000,000,000,000,000$1,381,373,456,343,941,000,000,000,000,000,000.00$47,791$5,475.61+$1.3838190899465547e+27MPVTTF

PVTTF vs EQR: Complete Analysis 2026

PVTTFStock

Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler's health, child's health, and pet's health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.

Full PVTTF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PVTTF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PVTTF vs SCHDPVTTF vs JEPIPVTTF vs OPVTTF vs KOPVTTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.